Title: Benserazide
CAS Registry Number: 322-35-0
CAS Name: DL-Serine 2-[(2,3,4-trihydroxyphenyl)methyl] hydrazide
Additional Names: N-(DL-seryl)-N¢-(2,3,4-trihydroxybenzyl) hydrazine
Molecular Formula: C10H15N3O5
Molecular Weight: 257.24
Percent Composition: C 46.69%, H 5.88%, N 16.33%, O 31.10%
Literature References: Peripheral decarboxylase inhibitor. Prepn: BE 619015; Hegedüs, Zeller, US 3178476 (1962, 1965 both to Hoffmann-La Roche). Inhibition of dopa decarboxylase in vitro and in vivo: W. P. Burkard et al., Experientia 18, 411 (1962); eidem, Arch. Biochem. Biophys. 107, 187 (1964). Synergy with dopa in vivo: G. Bartholini et al., Nature 215, 852 (1967); G. Bartholini, A. Pletscher, J. Pharmacol. Exp. Ther. 161, 14 (1968). Clinical comparison with carbidopa, q.v.: I. Kuruma et al., J. Pharm. Pharmacol. 24, 289 (1972). Clinical and pharmacokinetic profile: M.-H. Marion et al., Adv. Neurol. 45, 493 (1987). Review of pharmacology and clinical efficacy of decarboxylase inhibitors: R. M. Pinder et al., Drugs 11, 329-377 (1976).
Derivative Type: Hydrochloride
CAS Registry Number: 14919-77-8
Manufacturers' Codes: Ro-4-4602
Molecular Formula: C10H15N3O5.HCl
Molecular Weight: 293.70
Percent Composition: C 40.89%, H 5.49%, N 14.31%, O 27.24%, Cl 12.07%
Properties: White crystalline powder, mp 146-148°. Sol in water.
Melting point: mp 146-148°
Derivative Type: Combination with levodopa
CAS Registry Number: 37270-69-2
Additional Names: Co-beneldopa
Trademarks: Madopar (Roche); Madopark (Roche); Prolopa (Roche)
Therap-Cat: In combination with levodopa as antiparkinsonian.
Keywords: Antiparkinsonian. |